Any current/future new fundraising through debt or equity?

No explicit mention of any current or upcoming fundraising through debt or equity in the transcript. Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals. The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA. No indication from management about plans for incremental debt or equity raising. Focus appears to be on internal funding for expansion and ongoing initiatives.

Any current/future capex/capital investment/strategic investment?

Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation. Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand. Significant investment has already been made in the new agrochemical plant. Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years. Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals. Multiple initiatives under "Pinnacle 345" growth road

Future growth expectations in sales/revenue/volumes?

Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue. Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target. CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert. Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady. Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in

Future growth expectations in earnings/operating earnings/profits/EPS?

Jubilant Ingrevia aspires to grow revenue from a steady state of ~Rs. 4,500 crore to Rs. 12,000-13,000 crore in five years (Pinnacle 345 vision). Target EBITDA margin is 20%+ at the overall company level, with Specialty Chemicals expected to achieve 23%-25% EBITDA margins. Nutrition segment margins are anticipated to improve to 17%-18%+ with the addition of specialty products and new plants. The acetyl business is expected to sustain EBITDA margins around 10%-12%. Specialty Chemicals business aims to sustain 20%+ EBITDA and potentially reach closer to 24%-25% as new products and CDMO o

Current/ Expected Orderbook/ Pending Orders?

The company is in the advanced stages of discussions with an agrochemical customer for a contract; the first objective is to sign the contract before finalizing servicing details. The CDMO business is witnessing strong traction with new orders delivered during the quarter. There are multiple projects in advanced discussions across Pharma, Agro, and Semiconductor sectors. The Semiconductor-related CDMO opportunities have grown from 4-5 leads to 10-12 real leads, with samples already supplied to some customers. Growth aspiration for CDMO business is steady at 20%-25% CAGR, with a potenti

Jubilant Ingrevia LtdQ1 FY25Chemicals & Petrochemicals

Jubilant Ingrevia Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹638P/E: 32.9Market Cap: ₹10.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Jubilant Ingrevia aims to grow revenue 3x from FY24 to FY29, targeting Rs. 12,000 to Rs. 13,000 crore+ revenue.
Specialty Chemicals business expected to grow steadily with 23%-25% EBITDA margin aspirational target.
CDMO business (Pharma and Agro) to grow at least 20%-25% annually, with several advanced-stage opportunities to convert.
Agrochemical demand and volumes expected to recover gradually with easing inventory destocking; growth moderated but steady.
Nutrition business volumes increased ~14%-15% QoQ, with future improvement hinging on new food/cosmetic grade products launching in Q3 FY25.
New product lines (diketene, food-grade choline bitartrate) showing strong traction and contributing to volume growth.
Overall specialty segments reported stable or increasing volumes seasonally, with expectations of volume growth in FY25 compared to FY24.
Continued focus on customer centricity and ramping up new plants to sustain growth momentum.

Margin guidance

Category 1

Jubilant Ingrevia aspires to grow revenue from a steady state of ~Rs. 4,500 crore to Rs. 12,000-13,000 crore in five years (Pinnacle 345 vision).
Target EBITDA margin is 20%+ at the overall company level, with Specialty Chemicals expected to achieve 23%-25% EBITDA margins.
Nutrition segment margins are anticipated to improve to 17%-18%+ with the addition of specialty products and new plants.
The acetyl business is expected to sustain EBITDA margins around 10%-12%.
Specialty Chemicals business aims to sustain 20%+ EBITDA and potentially reach closer to 24%-25% as new products and CDMO opportunities scale up.
CDMO business is expected to grow at 20%-25% yearly, contributing significantly to profits.
Cost-saving initiatives are estimated to bring Rs. 120-140 crore annualized savings, enhancing profitability.
Overall, the company targets a 3x revenue and 4x EBITDA growth in five years from FY24 base, delivering strong earnings and EPS growth.

See what Jubilant Ingrevia Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

No explicit mention of any current or upcoming fundraising through debt or equity in the transcript.
Capital expenditure during the quarter was Rs.116 crore, primarily funded through internal accruals.
The company’s net debt as of June 30, 2024, was Rs.677 crore with a net debt-to-equity ratio of 1.5x based on trailing 12-month EBITDA.
No indication from management about plans for incremental debt or equity raising.
Focus appears to be on internal funding for expansion and ongoing initiatives.

Order book

Yes

The company is in the advanced stages of discussions with an agrochemical customer for a contract; the first objective is to sign the contract before finalizing servicing details.
The CDMO business is witnessing strong traction with new orders delivered during the quarter.
There are multiple projects in advanced discussions across Pharma, Agro, and Semiconductor sectors.
The Semiconductor-related CDMO opportunities have grown from 4-5 leads to 10-12 real leads, with samples already supplied to some customers.
Growth aspiration for CDMO business is steady at 20%-25% CAGR, with a potential jump based on lumpier agrochemical projects.
Overall, the company is building a robust CDMO opportunity pipeline for the coming years, although timing of revenue realization is uncertain due to the nature of the business.
Expansion plans for the next 5 years can be accommodated within the existing Gajraula and Bharuch facilities.

See what Jubilant Ingrevia Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Commissioned an agrochemical plant in January 2024 capable of producing both intermediates and active ingredients; currently under evaluation.
Plans to undertake modifications and incremental CAPEX in the agrochemical plant to meet demand.
Significant investment has already been made in the new agrochemical plant.
Expansion plans for fine chemicals with multipurpose plants at Gajraula and Bharuch facilities expected to serve growth for the next five years.
Ongoing CAPEX of Rs. 116 crore in Q1 FY25 funded primarily through internal accruals.
Multiple initiatives under "Pinnacle 345" growth roadmap, including investments in high potential product categories and sustainability efforts such as sourcing renewable energy.
CDMO business expected to grow with steady investments, targeting 25%-30% year-on-year growth; includes pharma, agro, and semiconductor opportunities.

Track Jubilant Ingrevia Ltd — get its next earnings analysis in your feed

How does Jubilant Ingrevia Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisJubilant Ingrevia Ltd

Rev 2Mar 1

See where Jubilant Ingrevia Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Jubilant Ingrevia Ltd rank in Chemicals & Petrochemicals?

Compare Jubilant Ingrevia Ltd against every Chemicals & Petrochemicals company (Q1 FY25) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Jubilant Ingrevia Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →